Alzheimer’s Disease Plasma

About Alzheimer’s Disease Plasma

Alzheimer’s Disease Plasma for Neurodegeneration Biomarker Research

Alzheimer’s Disease Plasma is collected from IRB-consented donors clinically diagnosed with Alzheimer’s disease and processed within one day of collection to preserve labile analytes such as proteins, peptides and metabolites. Alzheimer’s disease is a neurodegenerative disorder characterised by amyloid-beta plaque deposition, tau neurofibrillary tangles, synaptic and neuronal loss, and reactive glial responses. Plasma has become the central matrix for blood-based biomarker research in this field.

Why Plasma for Alzheimer’s Disease Research

• Blood-based biomarkers now track core Alzheimer’s pathology with a fidelity that was not achievable a decade ago. Plasma phosphorylated tau, and in particular p-tau217, corresponds closely with amyloid and tau pathology measured by PET imaging or cerebrospinal fluid, and other epitopes including p-tau181 and p-tau231 are also under active study.
• The plasma amyloid-beta 42 to 40 ratio decreases in the presence of cerebral amyloid pathology, but the effect size is small relative to the total analyte concentration, which is exactly why pre-analytical handling and matrix consistency matter so much for this measurement.
• Plasma neurofilament light chain reports neuroaxonal injury and glial fibrillary acidic protein reports astrocytic reactivity. Neither is specific to Alzheimer’s disease, and that lack of specificity is itself informative: they are used alongside p-tau to separate disease-specific from generic neurodegenerative signal.
• Pre-analytical variables including anticoagulant choice, time to centrifugation, tube surface binding and freeze-thaw cycles measurably affect amyloid and tau immunoassay results. Collection and processing details are documented per lot, and custom pre-analytical protocols can be specified for programmes with defined tube and handling requirements.
• APOE genotype is the dominant common genetic risk factor for late-onset Alzheimer’s disease and influences amyloid biomarker levels, so genotype-annotated donors materially change what a biomarker cohort can answer. Matched whole blood is available where DNA is required.
• With anti-amyloid monoclonal antibody therapies now in clinical use, plasma from donors across treatment states supports research into treatment-response markers and into the biomarker trajectories used for patient selection and monitoring.

Donor Stratification Available

• Clinical stage: mild cognitive impairment versus mild, moderate or severe Alzheimer’s dementia
• Cognitive assessment scores where documented, such as MMSE or MoCA
• Biomarker or imaging confirmation where documented, including amyloid PET or cerebrospinal fluid results
• APOE genotype where documented, and family history or early-onset presentation
• Treatment status: untreated, cholinesterase inhibitor, memantine, or anti-amyloid monoclonal antibody therapy
• Comorbid context including cerebrovascular disease, diabetes and other dementias; matched cognitively normal age-matched controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed Alzheimer’s disease donors
• Processed within one day of collection
• Anticoagulant and collection tube selection available on request
• Collection, processing and freeze-thaw history documented per lot
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes reported per lot

De-identified Donor Data

• Verified Alzheimer’s disease diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Additional Alzheimer’s disease-specific metadata available on request

Applications

• Plasma p-tau217, p-tau181 and p-tau231 immunoassay development and validation
• Amyloid-beta 42/40 ratio measurement and platform comparison studies
• Neurofilament light chain and GFAP quantification for neuroaxonal and glial injury
• Pre-analytical variability and matrix-effect characterisation
• Multi-marker panel development and diagnostic algorithm validation
• Plasma proteomics, lipidomics and metabolomics in neurodegeneration
• Treatment-response and disease-progression biomarker research
• Disease-state control matrix for neurology immunoassay qualification

Other Alzheimer’s Disease Specimen Types

• Alzheimer’s Disease Serum
• Alzheimer’s Disease Whole Blood
• Alzheimer’s Disease PBMC
• Alzheimer’s Disease Cerebrospinal Fluid

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Alzheimer’s disease plasma is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human plasma page.